Edwards Lifesciences Corp

Edwards Lifesciences Corp

EW

Market Cap$45.88B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Edwards Lifesciences CorpEdwards Lifesciences Corp11-42%8.70.1

Earnings Call Q1 2025

April 23, 2025 - AI Summary

Strong Q1 Performance: Edwards Lifesciences reported first-quarter sales of $1.041 billion, reflecting an 8% year-over-year growth. This was driven by increased adoption of TAVR (Transcatheter Aortic Valve Replacement) technology and the expanding TMTT (Transcatheter Mitral and Tricuspid Therapies) portfolio.
Updated TMTT Sales Guidance: The company raised its 2025 sales guidance for TMTT to $530-$550 million due to strong momentum and favorable foreign exchange rates. This represents a significant growth of approximately 60% from the previous year, indicating successful adoption of innovative technologies like Pascal and Evoque.
TAVR Growth Outlook: Edwards maintained its full-year TAVR sales growth guidance at 5%-7% and highlighted potential expansions with upcoming indication approvals for treating asymptomatic patients. The expectation is that the approval will happen in the second quarter, which could contribute to future growth.

Exclusive for Stockcircle Pro members

Sign upSign Up
$75.00

Target Price by Analysts

3.7% downsideEdwards Lifesciences Target Price DetailsTarget Price
$33.82

Current Fair Value

56.6% downside

Overvalued by 56.6% based on the discounted cash flow analysis.

Share Statistics

Market cap$45.88 Billion
Enterprise Value$43.97 Billion
Dividend Yield$0 (0%)
Earnings per Share$6.98
Beta1.13
Outstanding Shares586,900,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio10.98
PEG633.46
Price to Sales8.65
Price to Book Ratio4.58
Enterprise Value to Revenue7.94
Enterprise Value to EBIT26.7
Enterprise Value to Net Income10
Total Debt to Enterprise0.03
Debt to Equity0.11

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Edwards Lifesciences Corp

CEO: Michael Mussallem